Regeneron Pharmaceuticals Inc (REGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $98.84B
Last updated: Nov 17, 2026 at 4:34 PM ET
Regeneron Pharmaceuticals Inc (REGN) Statistics
Regeneron Pharmaceuticals (REGN) has a market cap of $98.84B and an enterprise value of $97.17B. Its trailing P/E is 18.5x.
Total Valuation
Enterprise value is 1.69% below the market cap, as cash exceeds debt.
| Market Cap | $98.84B |
|---|---|
| Enterprise Value | $97.17B |
| Latest price (Nov 17, 2026) | $957.76 |
Key Dates
The next earnings report is expected on Jan 28, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Nov 20, 2026.
| Next Earnings Date | Jan 28, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 30, 2026 |
| Next Ex-Dividend Date | Nov 20, 2026 |
| Next Payment Date | Dec 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.8x and 2.9x. Its year-end P/E ranged from 8.4x to 31.8x from 2016 to 2025.
| P/E Ratio | 18.5x |
|---|---|
| Forward P/E | 13.6x |
| P/S Ratio | 5.8x |
| Forward P/S | 5.3x |
| P/B Ratio | 2.9x |
| P/TBV Ratio | 3.0x |
| P/FCF Ratio | 25.5x |
| P/OCF Ratio | 20.4x |
| PEG Ratio | 1.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 15.3x EBITDA and 25.0x free cash flow.
| EV / Earnings | 20.2x |
|---|---|
| EV / Sales | 5.8x |
| EV / EBITDA | 15.3x |
| EV / EBIT | 16.9x |
| EV / FCF | 25.0x |
Price Statistics
The stock is up 38.44% over 52 weeks and trades 16.57% above its 50-day average.
| Beta (1Y) | 0.38 |
|---|---|
| 52-Week Change | +38.44% |
| 1-Month Change | +22.47% |
| 3-Month Change | +13.91% |
| 6-Month Change | +52.35% |
| 5-Year Change | +45.00% |
| 10-Year Change | +168.94% |
| Total Return (1Y) | +38.97% |
| Total Return (3Y CAGR) | +6.22% |
| Total Return (5Y CAGR) | +8.21% |
| Return vs SPY (1Y) | +20.80% |
| Max Drawdown (1Y) | -25.94% |
| Max Drawdown (3Y) | -59.69% |
| Sharpe Ratio (1Y) | 0.83 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $821.61 |
| 200-Day Average | $748.12 |
| 52-Week Range | $590.83 to $991.73 |
| RSI (14 Days) | 68.3 |
| Average Volume (20 Days) | 1.04M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.35x current liabilities, and total debt is 0.06x shareholder equity.
| Current Ratio | 3.35x |
|---|---|
| Quick Ratio | 2.89x |
| Debt / Equity | 0.06x |
| Debt / EBITDA | 0.32x |
| Debt / FCF | 0.52x |
| Interest Coverage | 122.77x |
Returns and Efficiency
Return on invested capital is 13.69% over the last 12 months, against a 5-year average of 13.38%.
| Return on Equity (ROE) | 14.38% |
|---|---|
| Return on Assets (ROA) | 10.85% |
| Return on Invested Capital (ROIC) | 13.69% |
| Return on Capital Employed (ROCE) | 15.01% |
| ROE (5Y Average) | 21.37% |
| ROA (5Y Average) | 16.27% |
| ROIC (5Y Average) | 13.38% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 0.80x |
| Receivables Turnover | 2.39x |
| Cash Conversion Cycle | 432 days |
Taxes
Income tax took 15.29% of pretax income over the last 12 months.
| Income Tax (TTM) | $869.40M |
|---|---|
| Effective Tax Rate | 15.29% |
Scores
REGN has an Altman Z-Score of 7.80, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.80 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $16.90B over the last 12 months is up 18.59% from the 12 months before.
| Revenue | $16.90B |
|---|---|
| Revenue Growth (YoY) | +18.59% |
| Gross Profit | $14.49B |
| Operating Income | $4.86B |
| Pretax Income | $5.69B |
| Net Income | $4.82B |
| EBITDA | $6.25B |
| EBIT | $5.73B |
| Reported EPS (TTM) | $51.87 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.43% of the $44.41B in total assets.
| Cash and Equivalents | $3.66B |
|---|---|
| Total Debt | $1.99B |
| Net Cash | $1.67B |
| Net Cash Per Share | $16.44 |
| Working Capital | $14.59B |
| Shareholder Equity | $33.50B |
| Book Value Per Share | $329.39 |
| Tangible Book Value | $32.18B |
| Tangible Book Per Share | $316.45 |
| Total Assets | $44.41B |
| Total Liabilities | $10.91B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.02B of capital spending, operating cash flow left $3.83B of free cash flow.
| Operating Cash Flow | $4.85B |
|---|---|
| Capital Expenditures | $1.02B |
| Free Cash Flow | $3.83B |
| FCF Per Share | $37.83 |
| Depreciation and Amortization | $512.90M |
| Dividends Paid | $383.00M |
| Share Repurchases | $3.04B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 28.79%, against a 5-year average of 35.70%.
| Gross Margin | 85.77% |
|---|---|
| Operating Margin | 28.79% |
| Pretax Margin | 33.66% |
| Net Margin | 28.51% |
| EBITDA Margin | 36.97% |
| EBIT Margin | 33.93% |
| FCF Margin | 22.65% |
| Gross Margin (5Y Average) | 85.93% |
| Operating Margin (5Y Average) | 35.70% |
| Net Margin (5Y Average) | 35.70% |
Growth
Revenue grew 5.62% a year over 3 years, and EPS fell 0.43% a year.
| Revenue Growth (3Y CAGR) | +5.62% |
|---|---|
| Revenue Growth (5Y CAGR) | +11.04% |
| EPS Growth (3Y CAGR) | -0.43% |
| EPS Growth (5Y CAGR) | +6.99% |
| FCF Growth (3Y CAGR) | -2.66% |
| FCF Growth (5Y CAGR) | +15.29% |
| Operating Income Growth (3Y CAGR) | -8.94% |
| Book Value Per Share Growth (2Y CAGR) | +12.87% |
| Tangible Book Per Share Growth (2Y CAGR) | +12.86% |
Dividends and Yields
REGN pays out 7.81% of earnings as dividends.
| Dividend Per Share (Annual) | $3.76 |
|---|---|
| Dividend Yield | 0.39% |
| Payment Schedule | Quarterly |
| Payout Ratio | 7.81% |
| FCF Payout Ratio | 10.01% |
| Earnings Yield | 5.41% |
| FCF Yield | 3.93% |
| Buyback Yield | 2.07% |
| Shareholder Yield | 2.47% |
Peer Position
Against 5 similar companies, REGN has the 5th highest P/E.
P/E RatioPeer median 33.2x
P/S RatioPeer median 17.5x
ROICPeer median -28.54%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +12.24%
Dividend YieldPeer median 0.00%
| P/E Ratio | 18.5x vs 33.2x median |
|---|---|
| P/S Ratio | 5.8x vs 17.5x median |
| ROIC | 13.69% vs -28.54% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +18.59% vs +12.24% median |
| Dividend Yield | 0.39% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 18.58% and EPS growth at 18.31% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +18.58% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +18.31% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About REGN
What is REGN's market cap?
Regeneron Pharmaceuticals has a market cap of $98.84B. Its enterprise value, which adds debt and subtracts cash, is $97.17B.
What is REGN's P/E ratio?
Regeneron Pharmaceuticals has a trailing P/E ratio of 18.5x and a forward P/E of 13.6x.
How many shares of REGN are outstanding?
Regeneron Pharmaceuticals has 101.70M shares outstanding. The count is down 1.83% from a year earlier.
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals pays $3.76 a share a year, a dividend yield of 0.39%.
How much debt does REGN have?
Regeneron Pharmaceuticals has $1.99B of total debt and $3.66B of cash and equivalents, a net cash position of $1.67B.
REGN pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts